Form 4: BioAge CMO Sells Shares After Option Exercise

BioAge Labs' Chief Medical Officer, Paul D. Rubin, exercised stock options and subsequently sold 18,000 shares of common stock for a profit.

Summary

• Paul D. Rubin, Chief Medical Officer of BioAge Labs, executed a pre-planned transaction on December 9, 2025.
• Rubin exercised options to acquire 18,000 shares of common stock at an exercise price of $6.57 per share.
• Concurrently, he sold all 18,000 shares of common stock at a price of $12.00 per share.
• The transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2024.
• Following these transactions, Rubin directly beneficially owns 0 shares of common stock.
• Rubin still holds 9,383 unexercised stock options, which vested or vest monthly at 1/48th of the total award, starting April 1, 2022.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the Chief Medical Officer selling all shares acquired through option exercise, which can be interpreted as profit-taking rather than increased investment, despite the transaction being pre-planned under a 10b5-1 plan.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating pre-planning and adherence to insider trading compliance protocols.
• The significant difference between the option exercise price ($6.57) and the sale price ($12.00) demonstrates a substantial profit for the reporting person from the exercised options.

Negatives

• The Chief Medical Officer sold all shares acquired through the option exercise, which could be perceived by some investors as a lack of increased confidence in the company's near-term stock performance, despite being a pre-planned transaction.

Risks

• Insider selling, even when pre-planned, can sometimes lead to negative market sentiment or speculation regarding the company's future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, such as option exercises and subsequent sales, are common occurrences in publicly traded companies. While pre-planned sales under Rule 10b5-1 plans are designed to avoid accusations of insider trading, the market often scrutinizes such activities for insights into management's perception of the company's valuation or future prospects.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider sale as a signal, potentially influencing their perception of the stock's value or future trajectory, despite the pre-planned nature of the transaction.

Key Dates

Recommendation

While the Chief Medical Officer's sale of shares after exercising options is a notable event, it was conducted under a pre-planned 10b5-1 trading plan, which mitigates some of the negative implications typically associated with insider selling. This single transaction, without additional context on company performance or strategic direction, is insufficient to warrant a strong buy or sell recommendation. Investors should hold and monitor future company announcements and financial reports for a more comprehensive investment decision.

Keywords

BioAge Labs, BIOA, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Paul D. Rubin, Chief Medical Officer, 10b5-1 Plan